acute myeloid leukaemia

News

Trial of 2seventy bio’s AML cell therapy paused after fatali...

Shares in 2seventy bio were on the slide this morning after the US biotech said Seattle Children’s Therapeutics had paused a clinical trial of its T-cell therapy for acute

News

Kura files $100m offer after menin inhibitor results in AML...

The development of Kura Oncology’s menin inhibitor ziftomenib for acute myeloid leukaemia has been held back by safety concerns in the past, but new data suggests the prog

News

Actinium radioligand aces AML trial as filings beckon

Survival doubled when Iomab-B was used as a conditioning regimen before a stem cell transplant.

News

Actinium eyes filing as conditioning drug for AML aces trial

Actinium Pharma is on course to submit its targeted radiotherapy for acute myeloid leukaemia (AML) patients needing a bone mar

News

Pleco raises €17m for tumour microenvironment drug

Pleco Therapeutics has closed a first-round financing, raising just over €17 million that it says will fund the development of its lead therapy for acute myeloid leukaemia (AML) through to

News

EHA: Survival data sets Daiichi Sankyo's quizartinib back on...

Three years after Daiichi Sankyo's FLT3 inhibitor quizartinib was rejected by the FDA, the drugmaker has reported the results of a new phase 3 trial that is key to getting the drug to the U

Trial of 2seventy bio’s AML cell therapy paused after fatali...

Kura files $100m offer after menin inhibitor results in AML...

Actinium radioligand aces AML trial as filings beckon

Actinium eyes filing as conditioning drug for AML aces trial

Pleco raises €17m for tumour microenvironment drug

EHA: Survival data sets Daiichi Sankyo's quizartinib back on...

Gilead claims first FDA nod for a hepatitis D therapy

Discover a new era of healthcare panel engagement: Grounded ...

acute myeloid leukaemia

Editor's Picks